Research Areas / Search Keywords
Nerve pain, nerve damage, neuropathy, peripheral neuropathy, diabetic neuropathy, small fiber neuropathy, burning pain, tingling, numbness, nerve repair, nerve regeneration, chronic pain, inflammation, tissue repair, tissue protection, diabetes, metabolic health, sarcoidosis, erythropoietin, cibinetide.
What Is ARA-290?
ARA-290, also called cibinetide, is an experimental peptide originally designed from part of the structure of erythropoietin (EPO).
EPO is best known as a hormone involved in producing red blood cells. But researchers discovered that EPO also activates pathways involved in protecting cells and responding to injury.
The problem is that using EPO can also significantly affect red blood-cell production.
ARA-290 was designed to investigate whether researchers could capture some of EPO’s tissue-protective and repair-related effects without stimulating red blood-cell production in the same way.
Why Are Researchers Interested in It?
The biggest area of interest is damaged nerves, particularly small nerve fibers.
Small nerve fibers help transmit sensations such as pain and temperature and also participate in automatic body functions.
Damage to these nerves can contribute to symptoms including:
- Burning or shooting pain
- Tingling
- Numbness
- Abnormal sensitivity
- Chronic nerve pain
ARA-290 has been studied in people with small-fiber neuropathy associated with sarcoidosis and type 2 diabetes.
How Does It Work?
ARA-290 is designed to activate a signaling system often referred to as the innate repair receptor.
Rather than primarily stimulating red-blood-cell production, activation of this pathway is being investigated for its involvement in:
reducing inflammatory responses → protecting injured cells → supporting tissue repair and recovery.
That’s one reason researchers became interested in whether ARA-290 might help damaged nerve tissue recover rather than simply masking nerve pain.
Evidence Snapshot
Laboratory Research: Yes
Animal Research: Yes
Human Research: Yes
Randomized Controlled Trials: Yes, but relatively small
FDA Approved: No
Overall Evidence: Early clinical / investigational
This puts ARA-290 further along scientifically than many compounds in the research-peptide market.
There have actually been controlled human trials rather than only cell and animal experiments.
What Has Human Research Found?
Small-Fiber Neuropathy & Sarcoidosis
An early randomized, double-blind pilot trial included 22 people with sarcoidosis and symptoms of small-fiber neuropathy.
Researchers reported improvement in a questionnaire measuring neuropathic symptoms among participants receiving ARA-290 compared with placebo. However, some pain and fatigue measurements improved similarly in both groups, illustrating why the results shouldn’t be interpreted as definitive proof.
Later controlled research also found changes in measurements of small nerve fibers, including increased corneal nerve-fiber density.
A subsequent Phase 2b randomized study involving 64 participants found that one cibinetide treatment group experienced a statistically significant increase in corneal small-nerve-fiber abundance compared with placebo.
Diabetic Neuropathy
ARA-290 has also been investigated in people with type 2 diabetes and painful neuropathy.
A Phase 2 study reported improvements in neuropathic symptoms as well as some measures involving glucose and lipid metabolism.
Researchers also observed evidence suggesting regeneration of corneal nerve fibers in a subgroup of participants with reduced nerve-fiber density.
These are interesting findings—but they’re still from relatively small studies and need confirmation in larger clinical trials.
What Do We Know?
ARA-290 isn’t simply a peptide with theoretical benefits based entirely on animal experiments.
There is human evidence suggesting potential effects involving:
nerve-fiber repair, neuropathic symptoms and tissue-protective signaling.
Researchers have also been able to objectively measure changes in nerve fibers rather than relying exclusively on participants reporting that they felt better.
That’s an important and interesting part of the research.
What Don’t We Know?
There are still major unanswered questions.
Research has not established ARA-290 as a general treatment for nerve pain or nerve damage.
We also don’t have strong evidence showing that it treats every form of neuropathy, chronic pain, inflammation, autoimmune disease, or metabolic dysfunction.
Larger and longer clinical trials would be needed to establish its effectiveness and long-term safety.
So while searches for things like “nerve repair” should absolutely bring ARA-290 up in your library, the profile needs to make clear that researchers are still figuring out what those early findings actually mean.
Research & Regulatory Status
ARA-290/cibinetide is not an FDA-approved medication.
The FDA does recognize cibinetide/ARA-290 as a defined substance in its substance-registration system, but FDA specifically notes that receiving a UNII identifier does not imply regulatory review or approval.
It therefore remains an investigational compound, despite having progressed into human clinical research.
Your Pep Resource Takeaway
ARA-290 is particularly interesting because researchers aren’t only asking:
“Can this reduce nerve pain?”
They’re investigating whether it might actually influence the biological processes involved in protecting and repairing damaged nerve fibers.
Small human trials have produced encouraging findings, including measurable changes in nerve-fiber density.
But the studies remain relatively small, and ARA-290 has not been established as an approved treatment for neuropathy or nerve damage.
This one has promising human evidence—but promising and proven aren’t the same thing.
Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, treatment, or purchasing recommendations. Experimental and research-only compounds may lack established human safety, efficacy, manufacturing, and regulatory standards.
Research Areas / Search Keywords:
Nerve health, nerve damage, nerve repair, nerve regeneration, nerve pain, neuropathy, peripheral neuropathy, small fiber neuropathy, diabetic neuropathy, diabetic nerve pain, chronic nerve pain, burning pain, burning feet, burning hands, pins and needles, tingling, tingling hands, tingling feet, numbness, numb hands, numb feet, nerve sensitivity, shooting pain, neurological health, neuroprotection, inflammation, chronic inflammation, inflammatory response, tissue protection, tissue repair, cellular repair, diabetes research, type 2 diabetes, metabolic health, sarcoidosis, erythropoietin, EPO, innate repair receptor, ARA-290, cibinetide.